Co-Authors
This is a "connection" page, showing publications co-authored by DAVID STEFFIN and HELEN HESLOP.
Connection Strength
2.760
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.746
-
Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Mol Ther. 2019 05 08; 27(5):900-901.
Score: 0.597
-
Complete Regression of Hepatoblastoma after Interleukin-15- and Interleukin-21-Coexpressing CAR T-Cell Therapy. N Engl J Med. 2026 Sep 10; 395(10):1029-1032.
Score: 0.249
-
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
Score: 0.224
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
Score: 0.220
-
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma. Res Sq. 2024 Apr 11.
Score: 0.211
-
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
Score: 0.210
-
Moving CAR-Ts to the outpatient clinic. Br J Haematol. 2023 11; 203(4):507-508.
Score: 0.203
-
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 02; 30(2):217-227.
Score: 0.051
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
Score: 0.049